As of October 2016, the accumulated revenue and total profit of the pharmaceutical manufacturing industry were 2,234.9 billion yuan and 235.6 billion yuan respectively, up 9.6% and 15.5% year-on-year. From a single month, October revenue and profit increased year-on-year. The speed was 6.4% and 27.2% respectively, which was 4.0 percentage points lower than the growth rate in September, and increased by 12.4 percentage points, maintaining the “stronger than the market†rating. The specific stock picking ideas are as follows:
Policy promotion + hospital appeal + medical insurance payment to promote explosive growth in the rehabilitation medical market. It is estimated that 6772 hospitals nationwide will complete the rehabilitation department construction in the next five years. The average rehabilitation equipment of a single hospital will be 4 million yuan, and the terminal market will reach 27.1 billion yuan. If it includes pension rehabilitation, rehabilitation hospitals, community rehabilitation and rehabilitation equipment and services for the disabled, its market size is nearly 100 billion. As the hospital vigorously built the rehabilitation department, rehabilitation equipment was the first to benefit, followed by rehabilitation services. Due to the scarcity of the standard, it is recommended to recommend the home medical equipment leader Yuyue Medical, and pay attention to the health of the health care service, which continues to expand;
.jpg)
Priority review and medical insurance catalogue adjustments are good for quality and innovative medicines. The focus is on Guangshengtang. The heavy product tenofovir is already in the priority review list, and the original drug has entered the local medical insurance in more than 20 provinces through drug price negotiation. The big probability will enter the national medical insurance through this adjustment. Livzon Group, Jichuan Pharmaceutical;
The Chinese medicine formula granule policy is expected to land during the year and the industry will expand at a high speed. It is recommended to recommend China Resources Sanjiu, the leading Chinese medicine formula granule leader, and Foci Pharmaceutical, which has product and technology reserves, to pay attention to Huatong Pharmaceutical;
"Two-vote system" or extended to the field of equipment, etc., mainly recommend IVD circulation leading Runda Medical. The "two-vote system" and "centralized procurement" systems will extend from the field of drug circulation to the field of equipment and consumables circulation, with emphasis on Runda Medical and Liuzhou Medicine and Nanjing Pharmaceutical;
Dingmin Pharmaceutical supply Amiodrone API and Amiodrone Intermediates with high purity and best price. The main products CAS No are as follows: 1951-26-4, 52490-15-0. Sample can be sent if you request.
Welcome to do business with us. Please email to us directly.
4-Hydroxy-Benzoy1,Arrhythmia Intermediates,Cas 52490-15-0
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com